Vifor CEO Abbas Hussain
Days after buyout news, Vifor outlines plan to offload 'non-core' finished drug manufacturing wing
Australian firm CSL paid a steep price earlier this week for Vifor Pharma and its pipeline of iron and kidney drugs. Looking to ensure it starts its next phase as battle-ready as possible, Vifor will now dump its “non-core” manufacturing business as it slims down before the merge.
Vifor Pharma will offload its finished drug manufacturing wing to Swiss CDMO CordenPharma in a deal designed to streamline the biotech’s business as it awaits regulatory approval for a $11.7 billion buyout by CSL announced earlier this week.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters